Elusys Therapeutics, Inc. Submits IND To Initiate Human Studies Of Anthrax Drug; Major Milestone In Company's Development Of Anthim

PINE BROOK, N.J.--(BUSINESS WIRE)--Feb. 28, 2005--Elusys Therapeutics, Inc. announced today that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to initiate human safety trials of its anti-anthrax drug, Anthim(TM). Anthim is a therapeutic monoclonal antibody being developed by Elusys to prevent and treat anthrax infections.

Back to news